Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ACE | P12821 | 10/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503523 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL503522 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL10835080 | 0.91 | SMN1; SMN2 (0.46) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL14374305 | 0.86 | ACE (0.60) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL12304830 | 0.86 | ACE (0.60) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL4671537 | 0.85 | ACE (0.61) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL4671532 | 0.85 | ACE (0.61) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL3780597 | 0.83 | ACE (0.60) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL4669921 | 0.83 | ACE (0.60) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| SCHEMBL4669890 | 0.83 | ACE (0.60) | SMN1; SMN2ACELMNAABCB11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173817-B2 | synthesis of substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form. Thus, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole is reacted with (R)-camphorsulfonyl-5- (and 6-)methoxy-2-[(3camphorsulfonyl chloride to form a mixture | HETERO DRUGS LIMITED (IN) | 2012-05-08 | — | — | US | claimed |
| US-20080076930-A1 | NOVEL STEREOSELECTIVE SYNTHESIS OF BENZIMIDAZOLE SULFOXIDES | HETERO DRUGS LIMITED (IN) | 2008-03-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076930-A1 | NOVEL STEREOSELECTIVE SYNTHESIS OF BENZIMIDAZOLE SULFOXIDES | CYP2S1, TPMT, CYP2B6 | SMN1; SMN2 2181/4885ACE 2458/4885LMNA 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.